These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38919953)

  • 1. miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR.
    Fuller RN; Vallejos PA; Kabagwira J; Liu T; Wang C; Wall NR
    Front Genet; 2024; 15():1393353. PubMed ID: 38919953
    [No Abstract]   [Full Text] [Related]  

  • 2. Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine.
    Fuller RN; Kabagwira J; Vallejos PA; Folkerts AD; Wall NR
    Onco Targets Ther; 2022; 15():1147-1160. PubMed ID: 36238134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs.
    Zhao B; Qin C; Li Z; Wang Y; Li T; Cao H; Yang X; Li T; Wang W
    Cancer Cell Int; 2022 Dec; 22(1):374. PubMed ID: 36457017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma.
    Shao F; Huang M; Meng F; Huang Q
    Front Pharmacol; 2018; 9():584. PubMed ID: 29922161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
    Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
    Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
    Fujiwara-Tani R; Sasaki T; Takagi T; Mori S; Kishi S; Nishiguchi Y; Ohmori H; Fujii K; Kuniyasu H
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Epithelial-Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel.
    Nakamura H; Watanabe M; Takada K; Sato T; Hikage F; Umetsu A; Muramatsu J; Furuhashi M; Ohguro H
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38790973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.
    Okazaki J; Tanahashi T; Sato Y; Miyoshi J; Nakagawa T; Kimura T; Miyamoto H; Fujino Y; Nakamura F; Takehara M; Ma B; Bando M; Kitamura S; Okamoto K; Muguruma N; Sogabe M; Takayama T
    Digestion; 2020; 101(6):794-806. PubMed ID: 31563901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
    Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
    Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
    PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heptadecanoic Acid, an Odd-Chain Fatty Acid, Induces Apoptosis and Enhances Gemcitabine Chemosensitivity in Pancreatic Cancer Cells.
    Kim HY; Moon JY; Cho SK
    J Med Food; 2023 Mar; 26(3):201-210. PubMed ID: 36716276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
    She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma.
    Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER; Wright CA; James M; Cooper SJ
    BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.